Chyloretroperitoneum is a rare complication of urological surgery. Here we report a case of chyloretroperitoneum that occurred in a 28-year-old man post living-donor transplantation. Twenty-nine days post transplantation, perirenal fluid collection and hydronephrosis were detected and percutaneous drainage was performed. The fluid was chylous and revealed a very high triglyceride concentration (1,197 mg/dL). Total parenteral nutrition and administration of octreotide were performed, but the leakage did not improve. On the contrary, the drainage fluid gradually increased to 1,600 mL/day, and a laparoscopic fenestration was performed owing to a concern about the adverse effects of massive lymph loss. Ascites temporarily appeared but disappeared 3 months post fenestration. To our knowledge, this is the first case report of pelvic chyloretroperitoneum post living-donor transplantation. Furthermore, if chyloretroperitoneum treatment using diet control or octreotide is ineffective, laparoscopic fenestration can be considered as a treatment option.

Keywords:
Chyloretroperitoneum, Renal transplantation, Laparoscopic fenestration, Octreotide
1.
Qi J, Gu ZQ, Chen F, Zhang L, Chen JH. Management of postoperative chyloretroperitoneum in adults.
Singapore Med J
. 2009 Sep; 50(9):e338–41.
2.
Negoro H, Oka H, Kawakita M. Two cases of chyloretroperitoneum following retroperitoneoscopic nephroureterectomy.
Int J Urol
. 2006 Apr; 13(4): 487–9.
3.
Lv S, Wang Q, Zhao W, Han L, Wang Q, Batchu N, et al. A review of the postoperative lymphatic leakage.
Oncotarget
. 2017 Apr; 8(40): 69062–75.
4.
Lucewicz A, Wong G, Lam VW, Hawthorne WJ, Allen R, Craig JC, et al. Management of primary symptomatic lymphocele after kidney transplantation: a systematic review.
Transplantation
. 2011 Sep; 92(6): 663–73.
5.
Ng ZQ, He B. A Proposed Classification System and Therapeutic Strategy for Chyle Leak After Laparoscopic Living-Donor Nephrectomy: A Single-Center Experience and Review of the Literature.
Exp Clin Transplant
. 2018 Apr; 16(2): 143–9.
6.
Guglielmo N, Melandro F, Nudo F, Mennini G, Levi Sandri GB, Berloco PB, et al. Chylous Leakage After a Laparoscopic Live-Donor Nephrectomy: Case Report and Literature Review.
Exp Clin Transplant
. 2016 Jun; 14(3): 338–40.
7.
Sharma S, Rizvi SJ, Modi PR. Medical management of chyloretroperitoneum following retroperitoneoscopic donor nephrectomy.
Indian J Nephrol
. 2014 Mar; 24(2): 129–30.
8.
Leibovitch I, Mor Y, Golomb J, Ramon J. The diagnosis and management of postoperative chylous ascites.
J Urol
. 2002 Feb; 167(2 Pt 1): 449–57.
9.
Ohtani O, Ohtani Y. Organization and developmental aspects of lymphatic vessels.
Arch Histol Cytol
. 2008 May; 71(1): 1–22.
10.
Huang HY, Hu SL. Scrotal cutaneous chylous reflux.
Br J Dermatol
. 2007 Apr; 156(4): 752–4.
11.
Tiong HY, Flechner SM, Zhou L, Wee A, Mastroianni B, Savas K, et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients.
Transplantation
. 2009 Jan; 87(2): 296–302.
12.
Lee HS, Joo DJ, Huh KH, Kim MS, Kim SI, Kim YS, et al. Laparoscopic fenestration versus percutaneous catheter drainage for lymphocele treatment after kidney transplantation.
Transplant Proc
. 2013 May; 45(4): 1667–70.
13.
Kawaguchi S, Nohara T, Shima T, Matsuyama S, Nose C, Yamahana J, et al. Massive Ascites in a Renal Transplant Patient after Laparoscopic Fenestration of a Lymphocele.
Case Rep Transplant
. 2016; 2016: 7491627.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.